Vol 53 No 06

"As urologists, we are the gatekeepers, and we must always perform the best possible surgery to optimize oncological outcomes," writes Jeremy Teoh, MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery).

Results of an exclusive Urology Times survey point to urologists preferring intravesical chemotherapy for treating BCG-unresponsive NMIBC.

Jonathan Rubenstein, MD, and Mark Painter tackle a coding question for treating stones.

Yōni.Fit bladder support was granted FDA 510(k) clearance in May 2024.

The freedom from re-intervention rate was 71%.

"This trial will be the benchmark for research reporting in the future," says Melissa R. Kaufman, MD, PhD, FACS.

Initial study results may be available as soon as the first half of 2026.

The investigators reported a median stone clearance of 96.44%.

In cohort A, the cystectomy-free rate at 36 months was 84%.

"I would argue that UGN-102 may very well represent a well-tolerated alternative to TURBT as primary treatment for patients with low-grade disease,” says Sandip M. Prasad, MD, MPhil.

"97% [of patients] remain progression free, and 84.5% avoided cystectomy, highlighting cretostimogene’s bladder-sparing potential,” said Mark D. Tyson II, MD, MPH.

Clarius Mobile Health said it will be demonstrating the application at the AUA Annual Meeting in Las Vegas, Nevada.

"In this large study of over 1500 men with an elevated PSA, we found that a low IsoPSA is incredibly reassuring,” says Christopher J. Weight, MD.

Overall, 71% of patients had no fragment greater than 2 mm following treatment.

The first patient in the trial will be receiving 67Cu-SAR-bisPSMA in combination with enzalutamide.